Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Vaccine maker stocks fall as Trump chooses RFK Jr. to lead HHS
Shares of vaccine makers fell as President-elect Donald Trump nominated Robert F. Kennedy Jr., a prominent vaccine skeptic, to lead the Department of Health and Human Services. Health policy experts have said a second Trump term could allow Kennedy to elevate anti-vaccine rhetoric.
Why vaccine stocks tumbled after Trump chose RFK Jr for US health secretary
The selection of vaccine sceptic Robert F Kennedy Jr by US President-elect Donald Trump to head the Department of Health and Human Services has sparked a market shock, with stocks of leading vaccine makers,
LIVE
Live updates: Trump selects Robert F. Kennedy Jr., a vaccine skeptic, as health secretary
Get the latest news on the transition to the new administration of President-elect Donald Trump and a new Congress.
Trump Picks Vaccine Skeptic Robert F. Kennedy Jr. to Lead Health & Human Services
In a move guaranteed to alarm many, President-elect Donald Trump has chosen Robert F. Kennedy Jr., a vocal opponent of vaccines and other tenets of mainstream health care, to head the massive U.S. Department of Health and Human Services (HHS).
Trump to select Robert F. Kennedy Jr. to lead HHS
The choice will roil many public health experts after his years of touting debunked claims that vaccines cause autism.
Trump taps Robert F. Kennedy Jr., vaccine skeptic, to lead health department
The nearly $2 trillion agency administers health-insurance programs for millions of Americans, approves medications and oversees vaccine safety.
Trump picks vaccine sceptic RFK Jr for health secretary
Donald Trump has picked vaccine sceptic and former independent presidential candidate Robert F Kennedy Jr as his health secretary, as the president-elect continues to build his new administration. Kennedy,
Trump picks anti-vaccine activist Robert F. Kennedy Jr. as health secretary
President-elect Donald Trump's plan to appoint Robert F. Kennedy Jr. to lead the Health and Human Services Department will put a prominent vaccine skeptic at the helm of the nation's sprawling public health apparatus.
1d
on MSN
BioNTech buys China's Biotheus to support oncology strategy
German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain ...
GlobalData on MSN
22h
BioNTech signs agreement to acquire Biotheus
BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
Investor's Business Daily on MSN
11h
BioNTech Stock Got A IBD RS Rating Lift
How Much Money To Invest Now. Is BioNTech Stock A Buy? BioNTech stock is building a consolidation with a 131.49 buy point.
FierceBiotech
2d
BioNTech pays $800M to take control of potential Keytruda killer
BioNTech
is upping its bet on a PD-L1xVEGF-A bispecific, paying $800 million upfront to buy its Chinese partner Biotheus ...
12h
The Analyst Landscape: 17 Takes On BioNTech
Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...
STAT
1d
BioNTech acquires its Chinese cancer drug partner
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...
AOL
1d
BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition
On Wednesday,
BioNTech
SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
BioPharma Dive
1d
BioNTech to buy Biotheus, gaining control of cancer bispecific
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
15h
Strategic Acquisition and Oncology Focus Justify BioNTech’s Buy Rating
John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...
3d
BioNTech (NASDAQ:BNTX) Raised to “Buy” at The Goldman Sachs Group
The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Trade
BNTX
Feedback